Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470808 | 0.89 | EPHX2 (0.42) | EPHX2LMNAMAPK1NLRP1DDR1 | |
| SCHEMBL2907081 | 0.85 | EPHX2 (0.53) | EPHX2LMNAMAPK1NLRP1DDR1 | |
| SCHEMBL3471137 | 0.85 | LMNA (0.46) | EPHX2LMNAMAPK1NLRP1DDR1 | |
| SCHEMBL2908128 | 0.81 | EPHX2 (0.58) | EPHX2LMNAMAPK1NLRP1DDR1 | |
| SCHEMBL3470911 | 0.81 | EPHX2 (0.62) | EPHX2 | |
| SCHEMBL2908406 | 0.81 | EPHX2 (0.54) | EPHX2LMNAMAPK1NLRP1DDR1 | |
| SCHEMBL13218652 | 0.80 | EPHX2 (0.65) | EPHX2LMNAMAPK1NLRP1DDR1 | |
| SCHEMBL3470030 | 0.79 | EPHX2 (0.49) | EPHX2ROCK2ROCK1 | |
| SCHEMBL3028889 | 0.77 | EPHX2 (0.59) | EPHX2LMNAMAPK1NLRP1DDR1 | |
| SCHEMBL2908865 | 0.77 | SCN9A (0.50) | EPHX2LMNAMAPK1NLRP1DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | claimed |
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
| WO-2009073772-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | EPHX1, REN, NCEH1 | EPHX2 9/4885LMNA 2136/4885MAPK1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.